COMPANY

OVERVIEW

Company Name CureApp (CureApp, Inc.)
Head Office 103-0001 Kodenma-Cho YS building 4th floor
12-5, Nihonbashi Kodenma-Cho, Chuo-ku, Tokyo, Japan
US subsidiary CureApp North America, Inc.
404 N Wolfe Rd, Sunnyvale CA, 94085
Established July 31, 2014
Founder Kohta Satake, Shin Suzuki

HISTORY

July 2014
  • CureApp, Inc was established.
December 2014
  • Selected for "I-Challenge! (the ICT Innovation Creation Challenge Program)" sponsored by the Ministry of Internal Affairs and Communications.
February 2015
  • Procured approximately 30 million yen by raising capital through third-party allocation.
  • Started clinical research on applications for treating nicotine addiction at Keio University Hospital.
October 2015
  • Procured approximately 70 million yen by raising capital through third-party allocation.
  • Granted the The Ministry of Economy, Trade and Industry "Monodzukuri Grant".
November 2015
  • Made the decision to adopt NEDO "research and development type venture support".
February 2016
  • Achieved second-class medical device manufacturing and sales business status.
October 2016
  • The Department of Gastroenterology and the University of Tokyo Medical School Hospital and NASH (nonalcoholic steatohepatitis) Clinical research of therapeutic applications began.
  • Obtained an Information Security Management System (ISMS).
January 2017
  • Selected for the "HIYAKU Next Enterprise" Program sponsored by the Ministry of Economy, Trade and Industry (dispatched to Silicon Valley).
February 2017
  • Procured approximately 380 million yen by raising capital through third-party allocation.
April 2017
  • Launched the "ascure smoking cessation program" as the first series of a mobile health program for corporate users.
October 2017
  • Started clinical tests on applications for treating nicotine addiction.
February 2018
  • Procured approximately 1.5 billion yen by raising capital through third-party allocation.
March 2018
  • Acquired the "Privacymark (P mark)," provided by JIPDEC.
June 2018
  • Started clinical research on hypertension treatment applications at multiple institutions, including Jichi Medical University Hospital.
  • Selected for the "J-Startup" Program sponsored by the Ministry of Economy, Trade and Industry.
March 2019
  • Established CureApp North America, Inc.
April 2019
  • Launched the "ascure STEPS" lifestyle improvement program, a mobile health program for corporate users.
May 2019
  • Announced the results of Japan's first "clinical test of an app" at the American Thoracic Society 2019 International Conference.
  • Announced the effectiveness of the treatment applications for nicotine addiction in smoking cessation outpatient clinics via Phase III clinical trials in Japan.
August 2019
  • Procured approximately 2.3 billion yen by raising capital through third-party allocation.